  
  
G/TBT/N/CAN/635  
8 March 2021  
(21-1928) Page: 1/2 
Committee on Technical Barriers to Trade  Original:  English /French  
 
  
NOTIFICATION  
The following notification is being circulated in accordance with Article 10.6  
 
1. Notifying Member:  CANADA   
If applicable, name of local government involved (Article 3.2 and 7.2):   
2. Agency responsible:  Health Canada  
Name and address (including telephone and fax numbers , email and website 
addresses, if available) of agency or authority designated to handle comments 
regarding the notification shall be indicated if different from above:   
Canada's Notification Authority a nd Enquiry Point  
Global Affairs Canada  
Technical Barriers and Regulations Division  
111 Sussex Drive  
Ottawa (Ontario) K1A 0G2  
Canada  
Tel: (343)203 -4273  
Fax: 613 -943-0346 
Email: enquirypoint@internati onal.gc.ca   
3. Notified under Article 2.9.2 [X], 2.10.1 [   ], 5.6.2 [   ], 5.7.1 [   ], other :  
4. Products covered (HS or CCCN  where applicable, otherwise national tariff 
heading. ICS numbers may be provided in addition, where applicable):  
Prescription status of medicinal ingredients for human use; Other (HS 300490); 
Pharmaceutics (ICS 11.120)  
5. Title, number of pages and langu age(s) of the notified document:  Notice of 
Amendment - Prescription Drug List (PDL): Vitamin D (2 pages, available in English and 
French)  
6. Description of content:  This Notice of Amendment notifies of the amendment the 
Prescription Drug List (PDL) qualifi er for Vitamin D to allow non -prescription status to 
products containing up to 62.5 µg or 2,500 International Units (IU)/day for oral use. Only 
the Human part of the PDL has been revised.   
7. Objective and rationale, including the nature of urgent proble ms where 
applicable:  Evolving scientific evidence; Protection of human health or safety  
8. Relevant documents:   
Health  Canada website: https://www.canada.ca/en/health -canada/services/drugs -
health -products/drug -products/prescr iption -drug-list/notices -changes/notice -intent -
vitamin -d.html  posted: 19 August 2020 (available in English and French).    
9. Proposed date of adoption:  19 August 2020  
Proposed date of entry into force:  24 February 2021  G/TBT/N/CAN/635  
 
- 2 - 
 
  10. Final date for comments:  Non applicable  
11. Texts available from:  National enquiry point [X] or address, telephone and fax 
numbers and email and website addresses, if available , of other body:   
The electronic version of the regulatory text can be downloaded at:  
https://www.cana da.ca/en/health -canada/services/drugs -health -products/drug -
products/prescription -drug-list/notices -changes/notice -amendment -vitamin -d.html  
  
https://www.canada.ca/fr/sante -canada/services/medicaments -produits -
sante/medicaments/liste -drogues -ordonnance/avis -concernant -modifications/avis -
modification -vitamine -d.html   
 